articleTop 1% cited

1,026 Experimental treatments in acute stroke

Annals of Neurology · 2006 · Vol. 59(3) · pp. 467–477

Victoria O’Collins(Austin Health)Malcolm Macleod(University of Edinburgh)Geoffrey A. Donnan(National Stroke Foundation)Laura L. Horky(National Stroke Foundation)Bart H. van der Worp(University Medical Center Utrecht)David W. Howells✉(University of Melbourne)

View via DOI Publisher page

Abstract

The results question whether the most efficacious drugs are being selected for stroke clinical trials. This may partially explain the slow progress in developing treatments. Greater rigor in the conduct, reporting, and analysis of animal data will improve the transition of scientific advances from bench to bedside.

Animal testing and alternatives Computational Drug Discovery Methods Traumatic Brain Injury and Neurovascular DisturbancesMedicineClinical trialStroke (engine)Mechanism (biology)Scope (computer science)Acute strokeIntensive care medicineDrugPhysical medicine and rehabilitationMedical physics

MeSH terms

AnimalsDisease Models, AnimalDrug Evaluation, PreclinicalHumansModels, BiologicalResearch DesignMeta-Analysis as TopicTreatment OutcomeNeuroprotective AgentsStrokePubMed

Citations

1,458

FWCI

61.98

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Guidelines for the Early Management of Patients With Acute Ischemic Stroke